The past decade has seen unprecedented growth in the biopharmaceutical industry, with the global compound annual growth rate (CAGR) estimated to reach 8.5% between 2017 and 2023. Fuelled by R&D successes which introduce new drug classes such as checkpoint inhibitors, viral gene therapies and antibody drug conjugates to the market, this growth is now threatening to overwhelm the industry. Rutger Oudejans Brand Director at bioLIVE, UBM explores solutions to these problems –namely taking lessons from issues faced by the small molecule industry 20 years ago.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/10/A-look-to-lessons-past_why-biopharma.pdf” width=”100%” height=”900px” style=”border:0;”]